Navigation Links
ProUroCare Medical Announces Offering of Replacement Warrants in Exchange for Early Exercise of Outstanding Warrants
Date:7/2/2010

MINNEAPOLIS, July 2 /PRNewswire-FirstCall/ -- ProUroCare Medical, Inc. (OTC Bulletin Board: PUMD) today announced that it has commenced a tender offer to holders of certain outstanding warrants to provide additional consideration for the exercise of such warrants.  The warrants subject to the tender offer are 1,752,760 publicly traded warrants and 2,752,947 unregistered warrants to purchase common stock that were issued on January 12, 2009 and will expire on January 7, 2014.  Also subject to the tender offer are 1,244,829 publicly traded warrants to purchase common stock that were issued on November 12, 2009 and will expire on November 12, 2012.  The tender offer commenced on Friday, July 2, 2010.

ProUroCare is offering to holders of the subject warrants the opportunity to exercise their existing warrants and receive, in addition to the shares of common stock purchased upon exercise, new, three-year replacement warrants.  The replacement warrants will have an exercise price of $1.30 per share and will be redeemable at ProUroCare's discretion at any time after the last sales price of its common stock equals or exceeds $4.00 for ten consecutive trading days.  ProUroCare must provide 30 days' prior written notice of a decision to redeem either the existing or replacement warrants.  Warrants not exercised during this 30-day period will be redeemed at $0.01 per warrant.  The purpose of the offer is to provide an incentive to exercise the subject warrants and thereby raise additional capital for ProUroCare.  

The offer is scheduled to expire at 4:00 P.M. Central Time on August 2, 2010, unless ProUroCare elects to extend the offer.  Subject warrants that are not tendered will retain their original terms including the $1.30 exercise price, expiration date and redemption terms.  Warrant holders may withdraw any tendered warrants before the expiration of the offer period and retain them on their original terms.  The subject warrants issued on January 12, 2009 may be redeemed at any time prior to expiration by ProUroCare.  The subject warrants issued on November 12, 2009 will be redeemable at ProUroCare's discretion at any time after the last sales price of its common stock equals or exceeds $4.00 for ten consecutive trading days.

The Offer Letter/Prospectus will be received by subject warrant holders in the near future (except for those who reside in states where the offer is not permitted).  For questions or assistance, or to request additional copies of the Offer Letter/Prospectus, which will be provided at ProUroCare's expense, warrant holders should contact Dick Thon, ProUroCare Medical, Inc., 6440 Flying Cloud Dr., Suite 101, Eden Prairie, MN 55344, (952) 698-1161.

About ProUroCare Medical, Inc.

ProUroCare Medical, Inc. is a publicly traded company engaged in the business of developing innovative medical imaging products. The company's current focus is the ProUroScan prostate imaging system, which is used to document abnormalities of the prostate detected by a Digital Rectal Exam (DRE).  Based in Minneapolis, Minn., ProUroCare's common stock is quoted on the OTCBB.

ProUroCare Medical, Inc. has filed a Registration Statement on Form S-4 (including a prospectus) and a Tender Offer Statement on Schedule TO with the Securities and Exchange Commission (the "SEC") for the tender offer and offering to which this communication relates. Before you accept the offer, you should read the Offer Letter/Prospectus in that registration statement, the related Letter of Transmittal, the Schedule TO and other documents ProUroCare has filed with the SEC, as well as any amendments or supplements thereto, for more complete information about ProUroCare, the tender offer and the offering. You may get these documents for free by visiting EDGAR on the SEC Web site at www.sec.gov.  Alternatively, ProUroCare will arrange to send you the Offer Letter/Prospectus and related documents, the Registration Statement on Form S-4 or the Tender Offer Statement on Schedule TO upon request by contacting Dick Thon, ProUroCare Medical, Inc., 6440 Flying Cloud Dr., Suite 101, Eden Prairie, MN 55344, (952) 698-1161. There shall there be no sales of the warrants or underlying common stock in any state in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state.   


'/>"/>
SOURCE ProUroCare Medical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. ProUroCare Medical Secures $885,000 in Financing
2. ProUroCare to Showcase Investigational Portable Platform for Its Prostate Imaging Device at AUA 2010
3. ProUroCare Medical Announces Filing of Request to Classify the Prostate Mechanical Imager ("PMI") as a Class II Device
4. ProUroCare Medical Elects Two New Directors
5. ProUroCare Medical Completes Multiple Site Clinical Study for Imaging Prostate Abnormalities
6. ProUroCare Medical Completes Clinical Trial at Second Study Site Using Digital Prostate Imaging Technology
7. ProUroCare Medical Inc. Announces Pricing of Equity Offering
8. China Medical Technologies to Announce Results for the First Fiscal Quarter Ended June 30, 2010 on August 16, 2010
9. Seniors and People with Disabilities Will Pay Steep Price for Medicares Competitive Bidding Program for Home Medical Equipment
10. Dehaier Medical Systems to Present to Investors at Global Hunter Securities 2010 China Investor Conference in San Francisco
11. Concord Medical Announces Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... 29, 2017  Novartis announced today that the ... the company,s Biologics License Application (BLA) filing and ... chimeric antigen receptor T cell (CAR-T) therapy, in ... patients with B-cell acute lymphoblastic leukemia (ALL). This ... a CAR-T. The priority review designation is expected ...
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 Research and ... Market, Reimbursement Policy, Patients Treated at Proton Therapy Centers & Forecast" ... ... 2021 from its current market size in 2016. The Untapped Proton Therapy ... than 1 Billion USD in 2016. Proton Therapy plays ...
(Date:3/29/2017)...  Zynex (OTCQB: ZYXI), an innovative medical technology company specializing ... for pain management, stroke rehabilitation, cardiac monitoring and neurological ... 2016 full-year investor webcast on Monday, April 3, 2017 at 9:00 a.m. ... expects to file its 2016 full year financial results ... ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 30, 2017 , ... Grass pollen is the main cause of hay ... the stuff. The season for grass pollen runs from May to July each year; with ... fever victim to do? HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense ...
(Date:3/29/2017)... ... ... Youth Futures International (YFI) premiered its Serve, Learn, & Empower program in 2009 ... have participated in the program every summer. The 2017 Serve, Learn, & Empower ... Visit http://www.ghana.yfiexperience.org to learn more. , “I have sent my daughter ...
(Date:3/29/2017)... ... 30, 2017 , ... Sports Brand EXOUS Bodygear announced today a special sale ... for the remaining days of March, the price will be only $19.97. The EXOUS ... of just $10 (regular retail price $19.97). , The special promotional prices are to ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... at a Walgreens store in Mississippi. AngioGenesis Labs, makers of HeartBoost, BrainBest and ... two southeastern states. Ingredients in HeartBoost, an over the counter heart healthy drink, ...
(Date:3/29/2017)... IN (PRWEB) , ... March 29, 2017 , ... ... Study, this webinar provides insight into the challenges employers face in trying to ... complexity of managing employee benefits programs? Adding to the growing complexity, companies ...
Breaking Medicine News(10 mins):